Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated virus COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Inactivated virus COVID-19 vaccines are a class of vaccines that utilize whole SARS-CoV-2 virus particles that have been rendered non-infectious, typically through chemical treatment with beta-propiolactone. Unlike mRNA or viral vector vaccines that focus primarily on the spike protein, inactivated vaccines present the entire viral structure to the immune system, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. These vaccines are usually formulated with an adjuvant, such as aluminum hydroxide, to enhance the immune response. Several manufacturers globally have developed and received authorization for these vaccines, including Sinovac (CoronaVac), Sinopharm (BBIBP-CorV), and Bharat Biotech (Covaxin), playing a significant role in global immunization efforts against COVID-19.
- Brand names
- CovaxinCoronaVacHayat-VaxVLA2001VLA-2001VLA 2001COVIran Barekat
- Other names
- Inactivated SARS-CoV-2 vaccineWhole-virion inactivated COVID-19 vaccine
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on inactivated virus COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated virus COVID-19 vaccine.